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The role of steroid treatment in drug-induced acute
interstitial nephritis (DI-AIN) is controversial. We performed
a multicenter retrospective study to determine the influence
of steroids in 61 patients with biopsy-proven DI-AIN, 52 of
whom were treated with steroids. The responsible drugs
were antibiotics (56%), non-steroidal anti-inflammatory
drugs (37%) or other drugs. The final serum creatinine was
significantly lower in treated patients while almost half of
untreated patients remained on chronic dialysis. Among
treated patients, over half showed a complete recovery of
baseline renal function, whereas the rest remained in renal
failure. There were no significant initial differences between
these two subgroups in terms of duration or dosage of
steroids. After withdrawal of the presumed causative drug,
we found that when steroid treatment was delayed (by an
average of 34 days) renal function did not return to baseline
levels compared to those who received steroid treatment
within the first 2 weeks after withdrawal of the offending
agent. We found a significant correlation between the delay
in steroid treatment and the final serum creatinine. Renal
biopsies, including three patients who underwent a second
biopsy, showed a progression of interstitial fibrosis related
to the delay in steroid treatment. Our study shows that
steroids should be started promptly after diagnosis of DI-AIN
to avoid subsequent interstitial fibrosis and an incomplete
recovery of renal function.
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Drug-induced acute interstitial nephritis (DI-AIN) represents
a significant cause of acute renal failure (ARF) in hospital
practice.1,2 As reported in some studies, about 15% of the
renal biopsies performed in patients with ARF demonstrated
a DI-AIN as the cause of the renal insufficiency.3 Antibiotics
and non-steroidal anti-inflammatory drugs (NSAIDs) are the
most frequently implicated agents, but the list of drugs that
can induce a DI-AIN is continuously increasing.1 A general
agreement exists about the discontinuation of the offending
drug as the first therapeutic step in patients with DI-AIN.
However, although renal function improves in a majority of
patients after this measure, serum creatinine (Scr) does not
return to its baseline value in a significant proportion of
cases.1,4
Controversy persists about the role of steroids in the
treatment of DI-AIN. Whereas some studies have reported a
more rapid and complete recovery of baseline renal function
in those patients treated with steroids,5–7 others have failed
to confirm these results.8–10 Available information about the
treatment of DI-AIN is based only on numerous case reports
and observational series including a short number of cases.
The absence of large retrospective series or prospective
controlled studies is the main cause of the inconsistency of
data regarding the most appropriate treatment for DI-AIN.
In this retrospective multicenter study, we analyzed the
influence of steroid treatment and other factors that could
influence the long-term outcome of DI-AIN. We gathered
61 patients with biopsy-proven DI-AIN, the largest series
studied so far. All the patients had a known baseline Scr
and all of them were followed during a period of time
sufficient to adequately establish their long-term outcome.
We found that steroid treatment induced a significant
beneficial effect on the normalization of renal function.
Furthermore, we found that a delay in the onset of steroid
treatment after discontinuation of the responsible drug was
the most significant factor to determine an incomplete
recovery of baseline Scr.
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RESULTS
A total of 61 biopsy-proven DI-AIN were analyzed. Demo-
graphic and clinical characteristics are expressed in Table 1.
All the patients had a baseline Scr (1.1±0.39; range
0.4–2.3 mg per 100 ml) obtained 7.5±4.6 (range 0.5–16)
months before the onset of DI-AIN. Baseline estimated
glomerular filtration rate (eGFR) was 71±25 (range
35–151 ml per min per 1.73 m2). Twenty-two patients
(36%) had a baseline eGFR lower than 60 ml per min per
1.73 m2. The drug responsible for the DI-AIN episode was
identified as an antibiotic in 34 patients (56%) (cephalo-
sporins in 15 patients, quinolones in 12, and penicillins
in 7), NSAIDs in 23 (37%), and other drugs (allopurinol,
omeprazole, ranitidine, and pimozide) in the remaining four
patients.
As expressed in Table 1, most of the patients presented
some of the classic clinical characteristics of DI-AIN (fever,
maculopapular rash, eosinophilia) with declining renal
function, although only eight patients (13%) showed these
three characteristics together. No significant differences in the
incidence of rash and fever were observed between DI-AIN
related to antibiotics, NSAIDs, and other drugs. Eosinophilia
was significantly less common among patients with DI-AIN
secondary to NSAIDs (18 vs 44% in DI-AIN not related to
NSAIDs, Po0.05). Most of the patients (40/61, 65%) showed
proteinuria, ranging from 0.4 to 6 g/24 h, and abnormalities
in the urinary sediment (microhematuria in 67% and
leukocyturia in 82%). Baseline proteinuria was significantly
higher in DI-AIN related to NSAIDs (1.4±1.4 g/24 h) in
comparison with DI-AIN secondary to other drugs (0.7±
0.8 g 24 h1; P¼ 0.05). Highest Scr oscillated between 1.5 and
13.3 mg per 100 ml with a mean of 5.7±3.3 mg per 100 ml.
Fourteen (23%) patients needed several sessions of hemo-
dialysis due to the severity of their ARF.
Comparison between patients treated (Group 1) and
untreated (Group 2) with steroids
Fifty-two patients were treated with steroids 23±17 (range
2–68) days after the withdrawal of the offending drug
(Group 1). Although steroid doses and duration of the treat-
ment were not uniform due to the multicenter character of
the study, the most common scheme of treatment consisted
of intravenous pulses of methylprednisolone (250–500 mg
daily for 3–4 consecutive days) followed by oral prednisone
(1 mg/kg/day) tapering off over 8–12 weeks. The remaining
nine patients did not receive steroids (Group 2). As expressed
in Table 2, there were no differences in baseline characteristics
(age, gender, baseline Scr and eGFR, type of offending drug,
duration of treatment, highest Scr and proteinuria, or the
interval between the withdrawal of the responsible drug
and the performance of renal biopsy) between Group 1 and
Group 2 patients. The final outcome of Group 1 patients
(steroid treatment) was significantly better than that of
Group 2 (no steroid treatment); as shown in Table 2, final Scr
was significantly lower in Group 1 patients and a significantly
higher proportion of Group 2 patients remained on chronic
dialysis after the DI-AIN episode (44.4 vs 3.8%). No side
effects attributable to steroid treatment were observed.
Comparison between steroid-treated patients who showed
a complete (Group 1a) or an incomplete (Group 1b)
recovery of baseline renal function
Twenty-eight out of 52 patients in Group 1 showed a
complete recovery of baseline renal function after steroid
treatment (Group 1a), whereas in the remaining 24 patients
(Group 1b) renal function did not reach the baseline values.
As expressed in Table 3, there were no significant differences
Table 1 | Clinical characteristics of the patients
Characteristic Value
Age (years) 57.7±17.4 (range 18–81)
Gender (M/F) 39/22
Baseline Scr (mg per 100 ml) 1.1±0.39 (range 0.4–2.3)
Baseline eGFR (ml per min per 1.73 m2) 71±25 (range 35–151)
Highest Scr (mg per 100 ml) 5.7±3.3 (range 1.5–13.3)
Oliguria 14 (23%)
Skin rash 14 (23%)
Fever 26 (42%)
Eosinophilia (4500 eosinophils/mm3) 21 (34%)
Proteinuria (g/24 h) 0.9±1.1 (range 0–6)
Microhematuria 41 (67%)
Leukocyturia 50 (82%)
eGFR, estimated glomerular filtration rate; F, female; M, male; Scr, serum creatinine.
Table 2 | Characteristics of Group 1 (steroid treatment) and Group 2 (no steroid treatment)
Group 1 (n=52) Group 2 (n=9) P-value
Age (years) 57.6±17.5 58.1±18 NS
Gender (M/F) (%) 61.5/38.5 77.8/22.2 NS
Baseline Scr (mg per 100 ml) 1.14±0.4 1.13±0.37 NS
Baseline eGFR (ml per min per 1.73 m2) 71±26 70±25 NS
Offending drug (antibiotics/NSAIDs/others) (%) 53.8/34.6/11.5 66.7/33.3/0 NS
Duration of the treatment (days) 13.4± (r 3–60) 12.6± (range 4–30) NS
Highest Scr (mg per 100 ml) 5.9±3.4 4.9±2.1 NS
Proteinuria (g/24 h) 1±1.2 (range 0–6) 0.6±0.6 (range 0–1.7) NS
Complete recovery of renal function 28 (54%) 3 (33%) NS
Chronic dialysis 2 (3.8 %) 4 (44.4 %) o0.001
Final Scr (mg per 100 ml) 2.1±2.1 (range 0.7–12.7) 3.7±2.9 (range 0.7–8.9) o0.05
Follow-up (months) 19±19 (range 6–60) 18±18 (range 6–56) NS
eGFR, estimated glomerular filtration rate; F, female; M, male; NS, not significant; NSAID, non-steroidal anti-inflammatory drug; Scr, serum creatinine.
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in the baseline characteristics of Group 1a and Group 1b
patients, although baseline renal function tended to be worse
and mean age older in Group 1b in comparison with Group
1a. Duration of the treatment with the offending drug was
longer in Group 1b, but this difference did not reach
statistical significance. Duration of steroid treatment was
similar in both groups, but the onset of steroid treatment
after drug withdrawal was significantly delayed in Group 1b
(34±17 vs 13±10 days in Group 1a, Po0.0001) as shown in
Table 3. The proportion of patients who received steroids
within the first 7 days and 15 days after the withdrawal of the
responsible drug was significantly higher in Group 1a than
in Group 1b are as follows: 35.7 vs 8.3%, Po0.05 and 67.9 vs
8.3%, Po0.0001, respectively (see Table 3). By multiple
logistic regression analysis, an interval longer than 7 days
between drug withdrawal and onset of steroid treatment
(odds ratio (OR) 6.6; 95% confidence interval (CI) 1.3–33.6,
P¼ 0.02) and the severity of interstitial fibrosis (OR 14.5;
95% CI 3.4–61, P¼ 0.0001) were the only clinical factors that
significantly increased the risk of an incomplete recovery of
renal function, whereas other clinical and analytical variables
such as age, gender, baseline Scr and eGFR, and highest Scr
or baseline had no significant influences.
As shown in Figure 1, significant correlation between the
delay in the onset of steroid treatment after drug withdrawal
and the final Scr was observed (r¼ 0.45, Po0.005). Recovery
of renal function, expressed by a 450% Scr decrease with
respect to the highest Scr, was significantly faster in Group 1a
as shown in Figure 2.
Histologic findings
A renal biopsy was obtained in all patients, although the
interval between drug withdrawal and its performance oscil-
lated widely. In all cases, a diffuse infiltration of inflamma-
tory cells composed of lymphocytes, eosinophils, monocytes,
and plasma cells into the interstitial compartment was
observed. Occasional focus of tubulitis was observed. No
correlation between the type of offending drug and the
histologic findings was observed. Peripheral eosinophilia did
not correlate with the number of eosinophils infiltrating renal
interstitium. Renal biopsies were always performed shortly
before the onset of steroid treatment in those patients who
were treated. The main histologic findings are shown in
Table 4. The severity of diffuse cellular infiltrates, as well as
their composition, was similar in all the patients. However,
differences were found in the degree of interstitial and
glomerular sclerosis. Main histologic findings are shown in
Table 4. Although there was a tendency to a more severe
interstitial fibrosis and glomerular sclerosis among Group 2
patients, this difference did not reach statistical significance.
A longer interval between drug withdrawal and the
performance of renal biopsy as well as a greater severity of
interstitial fibrosis were found in Group 1b (who did not
Table 3 | Characteristics of steroid-treated patients with a complete (Group 1a) or incomplete (Group 1b) recovery of baseline
renal function
Group 1a (n=28) Group 1b (n=24) P-value
Age (years) 55±18 (range 18–78) 60±16 (range 18–81) NS
Gender (M/F) (%) 61/39 62/38 NS
Baseline Scr (mg per 100 ml) 1.07±0.31 (range 0.6–1.9) 1.20±0.4 (range 0.6–2.3) NS
Baseline eGFR (ml per min per 1.73 m2) 77±29 (range 36–151) 65±21 (range 35–106) NS
Offending drug (antibiotics/NSAIDs/other) (%) 57/29/14 50/50/0 NS
Duration of the treatment (days) 11±7 (range 3–35) 16±16 (range 5–60) NS
Highest Scr (mg per 100 ml) 5.3±3.5 (range 1.5–13.3) 6.4±3.3 (range 2.9–12.7) NS
Proteinuria (g/24 h) 1.1±1.4 (range 0–6) 0.9±0.8 (range 0–3.4) NS
Final Scr (mg per 100 ml) 1.1±0.26 (range 0.7–1.8) 3.23±2.7 (range 1.5–12.7) o0.0001
Chronic dialysis 0 2 (8.3%) NS
Interval between drug withdrawal and onset of corticosteroid treatment (days) 13±10 (range 2–53) 34±17 (range 3–68) o0.0001
Patients with an interval between drug withdrawal and onset of corticosteroid
treatment o7 days
10 (35.7%) 2 (8.3%) o0.05
Patients with an interval between drug withdrawal and onset of corticosteroid
treatment o15 days
19 (67.9%) 2 (8.3%) o0.05
Duration of steroid treatment (days) 75±37 (range 20–180) 78±42 (range 16–165) NS
Follow-up (months) 16±17 (range 6–60) 24± 20 (range 6–63) NS
eGFR, estimated glomerular filtration rate; F, female; M, male; NS, not significant; NSAID, non-steroidal anti-inflammatory drug; Scr, serum creatinine.
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Figure 1 | Correlation between the delay in steroid treatment and
final Scr.
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completely recover baseline renal function in spite of steroid
treatment) in comparison with Group 1a (Table 4).
A second renal biopsy was performed in three patients
(two patients of Group 1b and one patient of Group 2) 33±7
(range 26–40) days after the performance of the first biopsy.
In the three cases, the interstitial cellular infiltrates observed
in the first biopsy showed a considerable size reduction in the
second biopsy. By contrast, large areas of interstitial fibrosis,
not observed in the first specimens, were prominent in the
second ones. Histologic changes between first and second
biopsy are illustrated in Figure 3.
Patients with DI-AIN due to NSAIDs
In 23 patients the drug responsible for the DI-AIN episode
was identified as an NSAID. We applied to these patients the
same definitions and statistical analysis performed in the
whole group of patients. Twenty patients were treated with
steroids; nine of them showed a complete recovery of baseline
renal function (NSAIDs-Group 1a), whereas in the remaining
11 patients renal function did not reach the baseline values
(NSAIDs-Group 1b). Characteristics of both subgroups
are shown in Table 5. There were no significant differences
in the baseline characteristics of both subgroups. As in the
whole group of patients, the main difference was the interval
between NSAID withdrawal and onset of steroid treatment,
which was significantly delayed in Group 1b patients (31.4±
15 vs 18.4±16 days (Po0.05). The proportion of patients
who received steroids within the first 15 days after withdrawal
of the NSAIDs was significantly higher in NSAID-Group 1a
than in NSAID-Group 1b: 44 vs 9.1% (Po0.05).
In the three NSAID-induced DI-AIN patients who did not
receive steroids, baseline Scr was 1±0.3 (range 0.7–1.3) mg
per 100 ml. Their final Scr was 1.9±1.1 (range 0.7–2.6) mg
per 100 ml.
DISCUSSION
The role of steroids in the treatment of DI-AIN remains
controversial. Despite the importance of this entity as a
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Figure 2 | Rate of renal function recovery, expressed by a
450% decrease of highest Scr, in Group 1a (final complete
recovery of renal function) and Group 1b (incomplete recovery).
Table 4 | Histologic findings
Group 1 Group 2 P-value Group 1a Group 1b P-value
Interval between drug
withdrawal and renal
biopsy (days)
22±17 (range 1–65) 26±24 (range 7–75) NS 13±10 (range 1–53) 33±17 (range 1–65) o0.0001
Interstitial fibrosis
Mild 32 (61.5%) 4 (44%) NS 25 (89.3%) 7 (29.2%) o0.0001
Moderate 14 (27%) 2 (22.2%) 3 (10.7%) 11 (45.8%)
Severe 6 (11.5%) 3 (33%) 0 6 (25%)
Figure 3 | Evolution of interstitial infiltrates. Dense interstitial
cellular infiltrates in the first renal biopsy of a patient of Group 1b
(top). In a second renal biopsy, obtained 33 days later, cellular
infiltrates have been largely replaced by fibrotic areas in the
interstitium (bottom).
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frequent cause of ARF,1–3 no prospective studies have
investigated the possible beneficial effect of steroids on
DI-AIN. Some studies have suggested a positive influence,
by showing a quicker and complete recovery of renal function
in those patients who received steroids.5–7 However, other
studies have failed to confirm these results.8–10 Thus, in the
largest series so far published, Clarkson et al.10 reported 60
patients with acute interstitial nephritis. More than 90% of
the patients had a DI-AIN and NSAIDs were the most
common etiology, accounting for 44% of cases. In this study,
no differences were found regarding final Scr among those
patients who received steroids and those who received only
conservative management. It should be considered, however,
that steroid treatment was considerably delayed, and that,
although not statistically significant, baseline Scr tended to be
higher among patients who were not treated with steroids.
On the basis of the available evidence, several reviews
recommend the use of steroids in DI-AIN only in those
patients in whom renal function does not recover after an
observational period of 7–15 days after the removal of the
offending drug.1 Nevertheless, many studies show that a
significant proportion of patients suffering DI-AIN do not
completely achieve their baseline renal function, persisting
with different degrees of chronic renal insufficiency after the
acute damage.1,4
Our study provides the largest series of biopsy-proven
DI-AIN gathered so far: 61 patients. Although the data were
retrospectively collected, advantages of the study were the
knowledge of the baseline renal function in all the included
patients and a follow-up sufficiently long to ascertain the
final outcome of every patient. We observed that the few
patients (9 out of 61, Group 2) who did not receive steroids
showed a final Scr significantly higher, and the proportion
of patients entering into chronic dialysis was significantly
higher than those who were treated with steroids (Table 2).
Furthermore, when analyzing the outcome of steroid-treated
patients, we found that some of them had completely
recovered their baseline renal function (Group 1a), whereas
the remaining (Group 1b) persisted with different degrees
of chronic renal insufficiency, despite an initial improvement
of renal function after the withdrawal of the causative drug.
The most salient difference between both subgroups was
the interval between drug withdrawal and the onset of steroid
treatment: 13±10 days in the former and 34±17 days in
the latter (Table 3). In addition, we found a significant
correlation between the delay in the onset of steroids and the
final Scr (Figure 1), and that an interval longer than 7 days
between drug withdrawal and onset of steroid treatment was
the only clinical factor that significantly increased the risk of
an incomplete recovery of renal function by multiple logistic
regression analysis.
Therefore, our study strongly suggests that steroid treat-
ment is indicated in DI-AIN and that it should be started
immediately or soon after the diagnosis to avoid the risk of
incomplete renal function recovery. No significant side effects
attributable to steroids were observed, probably due to the
short duration of the treatment (8–12 weeks).
We think that this latter point has not been sufficiently
emphasized in the previous literature, because most of the
patients with DI-AIN started to improve after the withdrawal
of the offending drug. However, as several previous studies
have pointed out and our study confirms, this initial
improvement is frequently exhausted and many patients
will exhibit chronic renal insufficiency as a consequence of a
DI-AIN episode. Recent studies have stressed the importance
of an even mildly reduced renal function, both in terms of
a future progression into end-stage renal failure and of an
increased risk of cardiovascular events.11
The rationale for an early institution of steroids in DI-AIN
is illustrated by the histologic findings of our study (Table 4).
Table 5 | Patients with DI-AIN due to NSAIDs treated with steroids
NSAIDs-Group 1a
(n=9)
NSAIDs-Group 1b
(n=11) P-value
Age (years) 51±24 (range 18–78) 61.2±16 (range 24–81) NS
Gender (M/F) (%) 66.7/33.3 45.5/54.4 NS
Baseline Scr (mg per 100 ml) 1±0.39 (range 0.6–1.9) 1.1±0.46 (range 0.6–2.3) NS
Baseline eGFR (ml per min per 1.73m2) 83±37 (range 36–151) 70±25 (range 35–106) NS
Duration of NSAIDs treatment (days) 12.4±10.9 (range 3–35) 25.4±20.4 (range 7–60) NS
Highest Scr (mg per 100 ml) 3.8±1.7 (1.5–7.7) 5.2±2.7 (range 3.1–12) NS
Proteinuria (g/24 h) 1.8±2.2 (range 0.33–6) 1.3±1 (range 0.1–3.4) NS
Final Scr (mg per 100 ml) 1.1±0.3 (range 0.7–1.6) 2.4±1 (range 1.6–4.8) o0.0001
Chronic dialysis 0 1 (9.1 %) NS
Interval between NSAIDs withdrawal and onset of corticosteroid
treatment (days)
18.4±16 (range 2–53) 31.4±15 (range 6–60) o0.05
Patients with an interval between NSAIDs withdrawal and onset
of corticosteroid treatment o7 days
3 (33 %) 1 (9.1 %) NS
Patients with an interval between NSAIDs withdrawal and onset
of corticosteroid treatment o15days
5 (44 %) 1 (9.1 %) o0.05
Duration of steroid treatment (days) 91.5±49.9 (range
20–180)
75.4±42 (range 30–180) NS
Follow up (months) 30±24.5 (range 6–60) 21.3±17 (6–60) NS
DI-AIN, drug-induced acute interstitial nephritis; NS, not significant; NSAID, non-steroidal anti-inflammatory drug; NSAIDs-Group 1a, complete recovery of baseline renal
function. NSAIDs-Group 1b, incomplete recovery.
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Steroid treatment was initiated after the performance of a
renal biopsy in all Group 1 patients. However, the interval
between drug withdrawal and the performance of renal
biopsy was significantly longer in Group 1b patients (with
incomplete recovery of renal function) than in Group 1a
patients. Although the typical histologic findings of DI-AIN
(diffuse infiltration of lymphocytes, monocytes, plasma cells,
and eosinophils into the interstitial compartment) were
observed in every case, the severity of interstitial fibrosis was
significantly worse in Group 1b patients. These findings
suggest that interstitial infiltrates characteristic of DI-AIN are
rapidly replaced by irreversible interstitial fibrosis and that
early steroid treatment could avoid this fibrotic process by
decreasing the severity of interstitial cellular infiltrates,
perhaps in a way similar to that of interstitial infiltrates of
acute rejection treated with steroids. Even more illustrative
are the three cases in whom a second renal biopsy was
performed 33±7 (range 26–40) days after the first biopsy. A
considerable size reduction of the interstitial cellular
infiltrates, which had been largely replaced by interstitial
areas of fibrosis, was observed (Figure 3). We think that the
histologic evolution of these patients is very interesting
because very few iterative biopsies have been published in DI-
AIN and it demonstrates that interstitial cellularity is rapidly
replaced (in the absence of steroid treatment) by extensive
fibrosis in a few weeks.
Some studies have suggested that DI-AIN caused by
NSAIDs could have a worse prognosis and a poorer response
to steroid treatment.12,13 We analyzed separately the outcome
of our patients with DI-AIN due to NSAIDs (Table 5). The
results were similar to those of the whole group, showing that
the delay in the onset of steroids was again the most
important determinant of an incomplete recovery of baseline
renal function. In those patients with DI-AIN due to NSAIDs
who achieved the baseline renal function after steroid
treatment, steroids were started 18.4±16 days after NSAIDs
withdrawal, an interval significantly shorter than in the group
that did not recover completely their baseline function
(31.4±15 days).
In conclusion, our data strongly suggest a beneficial
influence of steroids on the outcome of DI-AIN. Further-
more, according to our results, steroids should be started
immediately after the diagnosis of DI-AIN is established to
avoid the progressive replacement of interstitial cellular
infiltrates by interstitial fibrosis.
MATERIALS AND METHODS
We performed a retrospective analysis of patients with biopsy-
proven DI-AIN studied in 10 hospitals of the Comunidad de Madrid
in the period 1975–2006. The clinical suspicion of DI-AIN was based
on the presence of an acute renal function deterioration chrono-
logically related to a determined drug and accompanied by some
signs and symptoms characteristics of DI-AIN: fever, maculopapular
rash, eosinophilia, proteinuria, and urinary sediment abnormalities
(sterile leukocyturia, hematuria). The diagnosis of DI-AIN was
confirmed by a renal biopsy in all the patients included in the study.
Histologic diagnosis of DI-AIN was established in the presence of a
diffuse infiltration of inflammatory cells into the interstitial com-
partment with sparing of glomeruli and accompanied by different
degrees of interstitial edema and fibrosis. The infiltrating cell
population was composed of lymphocytes, monocytes, plasma
cells, and eosinophils. Patients with clinical or analytical data that
suggested systemic diseases were excluded. Three patients with
granulomatous DI-AIN were excluded because of the suspicion of
sarcoidosis in two and Sjo¨gren syndrome in one.
The presence of urinary tract obstruction or other urinary tract
abnormalities was excluded by appropriate radiological examina-
tions. In all the patients, the presence of urinary tract infection,
including renal tuberculosis, was ruled out by urine cultures.
Medical records of the patients were reviewed for this study.
All the patients had been admitted to the hospital during DI-AIN
and were discharged when renal function started to improve or
stabilize. Once identified, the responsible drug was withdrawn in
all patients. In those patients with antibiotic-related DI-AIN,
alternative antibiotic therapy was introduced, if indicated, after
the removal of the offending drug. A majority of patients, but
not all, were treated with corticosteroids. The interval between the
withdrawal of the responsible drug and the onset of steroid
treatment in those patients who were treated was variable. Steroids
were started after the performance of renal biopsy in all the patients.
After discharge, all patients were followed at regular intervals
(usually every 2 weeks in the first visits and thereafter every
6 months once Scr remained stable). The following data at
admission were obtained from medical records and analyzed for
this study: age, gender, blood pressure, abnormal findings on
physical examination, and complete baseline treatment. Analytical
study included a complete blood count, routine serum biochemistry
profile, urine sediment examination, urine cultures, and 24-h
proteinuria. Evolution of these analytical parameters during
admission and thereafter during follow-up was also recorded.
Estimated GFR was calculated by the MDRD (Modification of Diet
in Renal Disease)-4 formula.
All included patients had at least one Scr determination before
the episode of DI-AIN. The last determination of Scr, obtained
7.5±4.6 (range 0.5–16) months before the onset of DI-AIN, was
considered as baseline Scr.
The type of drug responsible for DI-AIN, duration of the
treatment, and day of drug withdrawal were carefully recorded.
In those patients who received steroids, dosage and duration were
also recorded. The highest Scr value registered was recorded, as
well as the need for acute dialysis. The intervals between offending
drug withdrawal and onset of steroid treatment and between drug
withdrawal and performance of renal biopsy were calculated in
every patient. Final Scr was defined as the value obtained 6 months
after withdrawal of the offending drug. An incomplete recovery
of baseline renal function was defined by an Scr value higher than
at least 25% of the baseline value.
Patients were divided into two groups according to steroid
treatment: Group 1, patients who received steroids and Group 2,
patients who were not treated with steroids. In addition, Group 1
patients were subdivided in two groups, according to whether the
recovery of baseline renal function had taken place or not (Group
1a, complete recovery of renal function and Group 1b, incomplete
recovery of renal function).
Renal biopsy specimens were revised for this study. The severity
of interstitial inflammation, interstitial fibrosis was graduated
between 0 and þ þ þ (absent, mild, moderate, and severe). The
percentage of glomeruli showing global sclerosis was recorded.
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Statistical analysis
Results are expressed as means±s.d. For statistical analysis, paired
and unpaired tests and non-parametric Mann–Whitney test were
used when appropriate. Qualitative variables were analyzed by
Fisher’s and w2-test. Multiple logistic regression analysis was
performed to determine the influence of different parameters on
the absence of a complete recovery of baseline renal function.
Survival analysis were performed with Kaplan–Meier curves and
differences estimated by log-rank test. Correlations between
quantitative variables were performed with Pearson’s correlation
coefficient. Statistics were calculated using SPSS for Windows,
version 11 (SPSS Inc., Chicago, IL, USA).
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